報價延遲最少15分鐘:2026/04/21 23:58 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
--/-0.73
|
|
企業價值
179.83M
|
| 資產負債 |
|
每股賬面淨值
-7.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
114.20M
|
|
每股收益
2.59
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets. |
